With Obesity on the Continued Rise in the U.S., More Anti-Obesity Drugs Are Heading for the Market

With Obesity on the Continued Rise in the U.S., More Anti-Obesity Drugs Are Heading for the Market

Eisai’s Obesity Drug Belviq Passes Cardiovascular Outcomes Test

  Eisai Co. Ltd./Arena Pharmaceuticals Inc.'s obesity drug Belviq (lorcaserin HCI) has proven that it doesn't pose cardiovascular risks in the CAMELLIA-TIMI 61 cardiovascular outcomes study, but it hasn't shown a benefit for reducing major events and it remains to be seen whether the new data will have any commercial effect on small sales. Patients taking Belviq … Συνεχίστε να διαβάζετε Eisai’s Obesity Drug Belviq Passes Cardiovascular Outcomes Test.